Cardiovascular Risk Stratification in Covid-19

Official Title

Brief Summary

This retrospective double-cohort study seeks to: 1. Describe the cardiovascular manifestations and electrophysiological (EP) substrate in COVID-19 infection and their association with clinical outcomes; and 2. Develop a method of cardiovascular risk stratification in COVID-19

Status

Completed

Conditions

COVID19

Cardiovascular Risk Factor

Eligibility Criteria

Inclusion Criteria:

- age >=18y

- available data on Covid19 test in the electronic medical record (either positive or
negative)

Exclusion Criteria:

- no data of Covid19 test

Eligibility Gender

All

Eligibility Age

Minimum: 18 Years ~ Maximum: N/A

Countries

United States

Locations

Oregon Health and Science University
Portland, Oregon, United States

Investigators

Larisa G Tereshchenko, MD, PhD, Principal Investigator
Oregon Health and Science University

NCT Number

NCT04555187

Keywords

COVID19

Cardiovascular Risk Factor

electrocardiogram

Risk stratification

MeSH Terms

COVID-19

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

Oregon Health and Science University

Cardiovascular Risk Stratification in Covid-19

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA